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RESULTS: Differences between countries about the average
clinical management patterns for a 2-year period are shown.
The economic impact concerns the overall cost (Ac  Fup)
as well as the breakdown between Ac and Fup costs. For
MI, overall costs range from 9513 Euros in Belgium to
18294 Euros in Austria. Weights of the follow-up costs
range from 33% in Portugal to 53% in Austria. For IS,
overall costs range from 5607 Euros in Austria to 56370
Euros in Switzerland. Differences also concern the weight of
the Fup costs (from 17% in Portugal to 75% in France).
CONCLUSION: Differences in overall cost and cost
breakdown can be explained by local treatment pattern
specificities and by the availability of specific and well-
adapted structures for patients rehabilitation. The follow-
up of an ischemic event should not be neglected in the glo-
bal economic burden assessment.
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OBJECTIVES: To i) compare the relative costs of two
leading atypical antipsychotics and ii) examine the contri-
bution of cost drivers of inpatient schizophrenia care.
METHODS: Data were pooled from a series of retrospec-
tive, single centre studies across 11 centers within 5 coun-
tries. Only patients with a diagnosis of schizophrenia or
schizoaffective disorder were considered.
RESULTS: A total of 601 patients received either risperi-
done (RIS; n  290) or olanzapine (OLA; n  311) as first
line therapy after admission. There were no baseline differ-
ences between both groups. The two products showed
equivalent efficacy rates (RIS: 78%, OLA: 77%; p  0.8)
but RIS patients achieved efficacy sooner (median  10
days) than OLA patients (median  18 days; p  0.001).
The mean modal daily doses were 4.9 mg (RIS) and 14.9
mg (OLA). OLA patients were more expensive (USD) than
RIS patients in both daily treatment costs (RIS: mean 
3.3; OLA: mean  6.5; p  0.0001) and daily all medica-
tion costs (RIS: mean  4.2; OLA: mean  7.3; p 
0.0001). The contribution of cost drivers was examined
through regression on the two key inpatient cost outcomes,
daily all medications costs (log transformed) and length of
stay (LOS; censored Cox regression). Daily all medication
costs were independently affected by prior hospitalizations
(), choice of atypical (OLA higher than RIS) and dose of
atypical () and these findings were over and above certain
intermediate factors. Length of stay was affected by prior
hospitalizations (-) and dose of atypical () again over and
above certain intermediate factors. Despite being counter-
intuitive, the data clearly indicate that 1st episode patients
stayed longest and the duration of stay continued to reduce
with further admissions.
CONCLUSION: The choice and dose of atypical is a ma-
jor driver of inpatient therapy cost. In addition the prior
disease span and severity, as measured by previous hospi-
talizations, is an important predictor of inpatient care
costs.
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BACKGROUND: Some observational studies have not
confirmed the beneficial effects of antihypertensive drug
treatment on the incidence of stroke and coronary heart
disease as demonstrated in randomized controlled clinical
trials (RCTs). This contradiction is probably due to the bi-
ased comparison in most observational studies between
treated hypertensive patients and prognostically different
reference groups such as normotensives or untreated hyper-
tensives regardless of their severity of hypertension and co-
existence of other cardiovascular risk factors.
OBJECTIVE: To assess the effect of the pharmacologic
treatment of hypertension under everyday circumstances
on the incidence of stroke.
METHODS: Approximately 45 000 men and women aged
20 years were examined in 2 population-based studies in
the Netherlands. A cohort of 2616 hypertensive subjects
who were either pharmacologically treated for hyperten-
sion (n  1318) or untreated hypertensives who were “can-
didates” for pharmacologic treatment on the basis of the
severity of their hypertension and the presence of other car-
diovascular risk factors (n  983) was followed up for a
mean duration of 4.6 years and follow-up was complete for
2369 (91%) subjects.
RESULTS: In this observational study, compared to un-
treated hypertensive subjects who were “candidates” for
pharmacologic treatment, subjects who were pharmacolog-
ically treated for hypertension had, after adjustment for dif-
ferences in prognostic factors, a 39% [95% confidence in-
terval (CI): 3–61%] reduced risk of stroke. About 46 [95%
CI: 29–599] hypertensive patients need to be treated phar-
macologically for 5 years to prevent one stroke in the gen-
eral Dutch population.
CONCLUSION: When a prognostically comparable refer-
ence group is used, the pharmacological treatment of hy-
pertension under everyday circumstances appears to be ef-
fective in the reduction of the incidence of stroke. The
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relative risk reduction that we found was similar to those
published on the basis of results from RCTs.
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OBJECTIVES: Dissemination of medical knowledge and
implementation of knowledge needs to be better under-
stood. Academic detailing can effectively change prescrib-
ing, but it is very resource demanding. This research com-
pares the effect of an educational intervention through
individual outreach visits and through a group approach,
using academic detailing.
METHODS: We conducted a randomized controlled trial
to measure the effect of two educational programs on pre-
scribing (individual intervention arm and group interven-
tion arm versus control arm) to reduce anticholinergic anti-
depressant (AAD) prescribing for the elderly. We included
all General Practitioners (GPs) and pharmacists (approx.
230) in the southwest Netherlands health district and used a
database covering all prescriptions to persons insured by the
national health insurance system in this area (approx.
240,000).
RESULTS: In the individual arm 43 of 70 GPs were visited;
in the group arm 5 of 7 groups (41 of 52 GPs) agreed to join
the program. Using an intention to treat analyses there was
a reduction in the incidence of AAD in elderly of 26% (95%
confidence interval 4%–48%) in the individual arm and
of 45% (8%–67%) in the group arm. The use of non-AAD
in the elderly increased by 40% (6%–83%) in the individual
arm and by 29% (7%–79%) in the group arm.
CONCLUSIONS: Both the individual and the group ap-
proach significantly decreased the incidence of AAD and in-
creased the incidence of non-AAD use in the elderly. These
approaches are practical means of improving the clinical ap-
propriateness of medication use on a large scale among pri-
mary care physicians.
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Dissention exists among health economists regarding the
measurement and inclusion of productivity costs in a cost-
utility analysis. Some health economists believe that produc-
tivity costs are captured by quality-adjusted life years
(QALYs) in the denominator of the cost-utility ratio. Others
argue that productivity costs should be measured mone-
tarily via the friction cost method or the human capital
method, and included in the numerator of the ratio.
OBJECTIVES: (1) To investigate the extent to which
changes in productivity costs are explained by changes in
QALYs. (2) To examine the difference between the hu-
man capital method and the friction cost method.
METHODS: An observational panel study with two sur-
vey waves was used to collect data. Surveys were admin-
istered through face-to-face interviews to a convenience
sample of 102 informal caregivers of the elderly.
RESULTS: Changes in QALYs did not explain absence
from paid labor, reduced productivity during paid labor,
and lost leisure productivity costs. However, changes in
QALYs did account for ten percent of the variance in
changes in lost unpaid labor (F  8.67, P  0.01). Fric-
tion cost estimates were significantly less than human
capital estimates in both the first and second waves of the
study (t  6.96, P  0.01, t  6.47, P  0.01).
CONCLUSIONS: Most productivity cost components
should be valued monetarily, and included in the numer-
ator of a cost-utility ratio. If the friction cost method is
used, rather than the human capital method, smaller esti-
mates of productivity costs will be obtained.
ECONOMIC & OUTCOMES STUDY RESULTS OF 
INFECTIOUS AND RESPIRATORY DISEASES
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OBJECTIVES: To examine the likely cost savings to the
NHS of reclassification of a medicine from prescription
only medicine (POM) to pharmacy (P) status.
METHODS: We used the General Practice Research Data-
base to look at changes in GP prescriptions for acyclovir
cream 5% before and after reclassification. To control for
the effects of prescription charges we categorized the data
into three patient age groups: 0–19, 20–59 and 60.
RESULTS: There was a 49% reduction in prescribing
rate in the 20–59 age group which has no prescription
charge exemptions on age grounds. For an average sized
general practice about 65 consultations would be saved
annually. Annual savings to the National Health Service
due to reclassification of one product are calculated to be
more than £5 million.
